% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rambau:141417,
      author       = {P. F. Rambau and R. A. Vierkant and M. P. Intermaggio and
                      L. E. Kelemen and M. T. Goodman and E. Herpel and P. D.
                      Pharoah and S. Kommoss and M. Jimenez-Linan and B. Y. Karlan
                      and A. Gentry-Maharaj and U. Menon and S. H. Polo and F. J.
                      Candido Dos Reis and J. A. Doherty and S. A. Gayther and R.
                      Sharma and M. C. Larson and P. R. Harnett and E. Hatfield
                      and J. M. de Andrade and G. S. Nelson and H. Steed and J. M.
                      Schildkraut and M. E. Carney and E. Høgdall and A. S.
                      Whittemore and M. Widschwendter and C. J. Kennedy and F.
                      Wang and Q. Wang and C. Wang and S. M. Armasu and F. Daley
                      and P. Coulson and M. E. Jones and M. S. Anglesio and C.
                      Chow and A. de Fazio and M. García-Closas and S. Y. Brucker
                      and C. Cybulski and H. R. Harris and A. D. Hartkopf and T.
                      Huzarski and A. Jensen and J. Lubiński and O. Oszurek and
                      J. Benitez and F. Mina and A. Staebler and F. A. Taran and
                      J. Pasternak and A. Talhouk and M. A. Rossing and J. Hendley
                      and R. P. Edwards and S. Fereday and F. Modugno and R. B.
                      Ness and W. Sieh and M. A. El-Bahrawy and S. J. Winham and
                      J. Lester and S. K. Kjaer and J. Gronwald and P. Sinn and P.
                      A. Fasching and J. Chang-Claude$^*$ and K. B. Moysich and D.
                      D. Bowtell and B. Y. Hernandez and H. Luk and S. Behrens$^*$
                      and M. Shah and A. Jung and P. Ghatage and J. Alsop and K.
                      Alsop and J. García-Donas and P. J. Thompson and A. J.
                      Swerdlow and C. Karpinskyj and A. Cazorla-Jiménez and M. J.
                      García and S. Deen and L. R. Wilkens and J. Palacios and A.
                      Berchuck and J. M. Koziak and J. D. Brenton and L. S. Cook
                      and E. L. Goode and D. G. Huntsman and S. J. Ramus and M.
                      Köbel},
      collaboration = {A. Group},
      title        = {{A}ssociation of p16 expression with prognosis varies
                      across ovarian carcinoma histotypes: an {O}varian {T}umor
                      {T}issue {A}nalysis consortium study.},
      journal      = {The journal of pathology: clinical research},
      volume       = {4},
      number       = {4},
      issn         = {2056-4538},
      address      = {Chichester},
      publisher    = {Wiley},
      reportid     = {DKFZ-2018-01923},
      pages        = {250 - 261},
      year         = {2018},
      abstract     = {We aimed to validate the prognostic association of p16
                      expression in ovarian high-grade serous carcinomas (HGSC)
                      and to explore it in other ovarian carcinoma histotypes. p16
                      protein expression was assessed by clinical-grade
                      immunohistochemistry in 6525 ovarian carcinomas including
                      4334 HGSC using tissue microarrays from 24 studies
                      participating in the Ovarian Tumor Tissue Analysis
                      consortium. p16 expression patterns were interpreted as
                      abnormal (either overexpression referred to as block
                      expression or absence) or normal (heterogeneous). CDKN2A
                      (which encodes p16) mRNA expression was also analyzed in a
                      subset (n = 2280) mostly representing HGSC (n = 2010).
                      Association of p16 expression with overall survival (OS) was
                      determined within histotypes as was CDKN2A expression for
                      HGSC only. p16 block expression was most frequent in HGSC
                      $(56\%)$ but neither protein nor mRNA expression was
                      associated with OS. However, relative to heterogeneous
                      expression, block expression was associated with shorter OS
                      in endometriosis-associated carcinomas, clear cell [hazard
                      ratio (HR): 2.02, $95\%$ confidence (CI) 1.47-2.77, p <
                      0.001] and endometrioid (HR: 1.88, $95\%$ CI 1.30-2.75, p =
                      0.004), while absence was associated with shorter OS in
                      low-grade serous carcinomas (HR: 2.95, $95\%$ CI 1.61-5.38,
                      p = 0.001). Absence was most frequent in mucinous carcinoma
                      $(50\%),$ and was not associated with OS in this histotype.
                      The prognostic value of p16 expression is histotype-specific
                      and pattern dependent. We provide definitive evidence
                      against an association of p16 expression with survival in
                      ovarian HGSC as previously suggested. Block expression of
                      p16 in clear cell and endometrioid carcinoma should be
                      further validated as a prognostic marker, and absence in
                      low-grade serous carcinoma justifies CDK4 inhibition.},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30062862},
      pmc          = {pmc:PMC6174617},
      doi          = {10.1002/cjp2.109},
      url          = {https://inrepo02.dkfz.de/record/141417},
}